Canagliflozin 300mgTablet
Diabetes & Metabolic

Canagliflozin 300mg

Canagliflozin

First SGLT2 inhibitor approved with cardiovascular and renal outcome benefits in the CANVAS and CREDENCE trials. Manufactured by Cipla and Natco for diabetes export.

Strengths

100mg / 300mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Canagliflozin 100mg / 300mg
Dosage Form
Tablet
Available Strengths
100mg / 300mg
Packing
10 tablets/strip
Route of Administration
Oral, before first meal of the day
Dosage
100mg once daily before breakfast; may increase to 300mg for additional glycemic control
Indications
Type 2 diabetes, diabetic kidney disease, cardiovascular risk reduction in T2DM
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 30°C
Shelf Life
36 months
Side Effects
Genital mycotic infections, UTI, polyuria, hypotension, increased LDL, lower limb amputation risk
Precautions
Lower limb amputation risk (CANVAS); monitor for DKA; volume depletion; genital infections; avoid if eGFR <30; Fournier's gangrene risk

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Glimepiride 2mgTablet

Glimepiride 2mg

Glimepiride

Third-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion via selective SUR1 receptor binding, offering a lower hypoglycemia risk compared to earlier sulfonylureas due to glucose-dependent activity. The most cost-effective oral antidiabetic agent in its class and a cornerstone of type 2 diabetes management in emerging markets.

1mg / 2mg / 3mg / 4mg
Sitagliptin 100mgTablet

Sitagliptin 100mg

Sitagliptin Phosphate

First-in-class DPP-4 inhibitor that amplifies incretin-mediated glucose-dependent insulin secretion while suppressing glucagon, offering glycemic control without weight gain or intrinsic hypoglycemia risk. Once-daily dosing, renal dose adjustment flexibility, and a decade-long cardiovascular safety record make it a globally preferred add-on antidiabetic.

25mg / 50mg / 100mg
Vildagliptin 50mgTablet

Vildagliptin 50mg

Vildagliptin

Selective DPP-4 inhibitor with potent enzyme inhibition that improves glycemic control through enhanced incretin-mediated insulin secretion and suppressed post-meal glucagon release. Widely prescribed as a fixed-dose combination with metformin (Galvusmet) offering convenient dual-mechanism therapy without weight gain.

50mg

Need bulk pricing for Canagliflozin 300mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote